Status:
COMPLETED
The Effect of the CytoSorb® Filter to Remove Anticoagulants From the Circulation During Emergency Surgery for Aortic Dissection
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
University of Oslo
Conditions:
Aortic Dissection
Factor X Inhibition
Eligibility:
All Genders
18-100 years
Brief Summary
The direct oral anticoagulants (DOACs) and particularly the FXa inhibitors are a concern in patients presenting with type A aortic dissection as this may contribute to severe bleeding complications. T...
Eligibility Criteria
Inclusion
- Indication for urgent surgery for proximal aortic disease
- Treatment with FXa inhibitor for more than 2 weeks
- Measured concentration of FXa inhibitor in therapeutic range (\>50 ng/mL) at the time of admission.
- Intraoperative use of Cytosorb® hemadsorber.
Exclusion
- • Low FXa inhibitor concentration (\<50 ng/mL) at the time of admission
Key Trial Info
Start Date :
April 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 5 2024
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT05235178
Start Date
April 18 2021
End Date
November 5 2024
Last Update
May 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oslo University Hospital
Oslo, Oslo County, Norway, 0450